TOS FERINA EN LA INFANCIA





TOS FERINA EN LA INFANCIA

(especial para SIIC © Derechos reservados)
Reseña de la epidemiología cambiante de la tos ferina en los países desarrollados y comparación de las estrategias potenciales para evitar la infección por Bodetella pertussis en los lactantes.
wood9.jpg Autor:
Nicholas Wood
Columnista Experto de SIIC
Artículos publicados por Nicholas Wood
Coautores
Peter McIntyre* Elizabeth Elliot** 
MB, BS, FRACP, FAFPHM, PhD, Westmead, Australia*
MD, FRACP, FRCP, FRCPCH, Westmead, Australia**
Recepción del artículo
26 de Septiembre, 2006
Aprobación
18 de Noviembre, 2006
Primera edición
29 de Mayo, 2007
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
Los lactantes menores de 6 meses tienen las tasas más elevadas de infección por Bordetella pertussis y la morbimortalidad más alta secundaria a la enfermedad, pero son demasiado pequeños para estar protegidos por los esquemas de vacunación actuales. En los países con programas de inmunización bien establecidos contra la tos ferina en la infancia, la principal fuente de infección para los lactantes son los adultos y adolescentes. La inmunidad luego de un curso primario de vacunación contra la tos ferina disminuye después de 5 a 10 años. Este artículo reseña la epidemiología cambiante de la tos ferina en los países desarrollados y compara las estrategias potenciales para evitar la infección por B. pertussis en los lactantes. La vacunación universal de adultos y adolescentes probablemente evite en mayor medida los casos de enfermedad, pero está limitada por los costos y las dificultades en la implementación. Las estrategias de vacunación selectivas dirigidas a los padres y otros contactos cercanos de los bebés son menos costosas y tienen ventajas potenciales en cuanto a la implementación; aunque no se instituyeron a nivel poblacional en ningún país. La inmunización más temprana en los lactantes también es dificultosa ya que los pocos estudios sobre vacunación en los recién nacidos mostraron que si bien los niveles de anticuerpos ascienden más rápidamente, no son tan persistentes a los 7 a 12 meses en comparación con los esquemas actuales; no se realizaron ensayos sobre la inmunización con la vacuna acelular en embarazadas. Es necesario contar con datos adicionales y una evaluación formal de la costo-efectividad antes de establecer la preferencia de una estrategia sobre otra.

Palabras clave
tos ferina, lactante, prevención, estrategias de vacunación


Artículo completo

(castellano)
Extensión:  +/-12.2 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Infants under 6 months of age, have the highest rates of pertussis infection and the highest morbidity and mortality from pertussis, but are too young to be protected by current vaccination schedules. In countries with well-developed childhood pertussis immunisation programs, adults and adolescents are now the primary sources of infection for infants. Immunity following a primary course of pertussis vaccine wanes after 5-10 years. This paper reviews the changing epidemiology of pertussis in developed countries and compares potential strategies to prevent pertussis infection in infants. Universal adult/adolescent vaccination probably would prevent most disease but is challenging because of cost and implementation problems; "cocoon" strategies targeting parents and other close contacts of new babies are less costly and have potential advantages for implementation but have not been instituted at population level in any country. Earlier infant vaccination, is also problematic as the few studies of pertussis vaccination in the newborn show that although antibody levels rise earlier, they do not persist well at 7-12 months compared to current schedules and no acellular pertussis vaccine trials in pregnant women have been conducted. Additional trial data and formal evaluation of cost-effectiveness is needed before any strategy can be clearly preferred.

Key words
pertussis, infant, prevention, vaccination strategies


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Pediatría
Relacionadas: Atención Primaria, Medicina Familiar, Medicina Interna, Salud Pública



Comprar este artículo
Extensión: 12.2 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Nicholas Wood, National Centre for Immunisation Research and Surveillance The Children's Hospital at Westmead, NSW 2145, Locked Bag 4001, Westmead, Australia
Bibliografía del artículo
1. Plotkin SA, Orenstein WA (editors). Vaccines. 3rd ed. Philadelphia, PA: WB Saunders; 1999.
2. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 28:1230-1237, 1999.
3. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Vaccine preventable diseases and vaccination coverage in Australia, 1999-2000. Commun Dis Intell 26:S1-111, 2002.
4. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 22:22-27, 2003.
5. Baron S, Mjamkepo E, Gimprel E et al. Epidemiology of pertussis in French hospital in 1993-1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 17:412-418, 1998.
6. Tanaka M, Vitek C, Pascual F et al. Trends in pertussis among infants in the United States, 1980-1999. JAMA 23:2968-2975, 2003.
7. Godfroid F, Denoel P, Poolman J. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence. Expert Rev Vaccines 4:757-778, 2005.
8. Crowcroft NS, Andrews N, Rooney C, Brisson M, Miller E. Deaths from pertussis are underestimated in England. Arch Dis Child 86:336-8, 2002.
9. Crowcroft NS, Pebody R. Recent developments in pertussis. Lancet 367:1926-1936, 2006.
10. De Melker H, Versteegh F, Schellekens J et al. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 53:106-113, 2006.
11. Tan T, Trindale E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 24:S10-18, 2005.
12. Menzies R, Wang H, McIntyre PB. Has pertussis increased in New South Wales over the past decade? An evaluation using hospitalisation and mortality data versus notifications 1988-2002. New South Wales Public Health Bulletin 14:71-6, 2003.
13. Elliot E, McIntyre P, Ridley G et al. National study of infants hospitalised with pertussis in the acellular petussis vaccine era. Pediatr Infect Dis J 23:246-252, 2004.
14. Celentano L, Massari M, Paramatti D et al. Resurgence of pertussis in Europe. Pediatr Infect Dis J 24:761-765, 2005.
15. Juretzko P, Von Kries R, Hermann M et al. Effectiveness of acellular pertussis vaccine assessed by hospital based active surveillance in Germany. Clin Infect Dis 35:162-167, 2002.
16. Hviid A, Stellfield M, Andersen P et al. Impact of routine vaccination with a pertussis tpxoid vaccine in Denmark. Vaccine 22:3530-3534, 2004.
17. Crowcroft N, Booy R, Harrison T et al. Severe and unrecognised: pertussis in UK infants. Arch Dis Child 88:802-806, 2003.
18. Cherry J. The epidemiology of pertussis: A comparison of the epidemiology of the disease pertussis with the epidemiology pf Bordetella pertussis infection. Pediatrics 115:1422-1427, 2003.
19. CDC Pertussis - United States, 2001-2003. MMWR 54:1283-1286, 2005.
20. CDC, unpublished data, 2004 - Pertussis outbreak in an Amish community - Kent County, Delaware, September 2004-February 2005 MMWR 55:817-821, 2006.
21. Galanis E, King A, Varughese P et al. Changing epidemiology and emerging risk groups for pertussis. CMAJ 174:451-452, 2006.
22. Crowcroft N, Stein C, Duclos P et al. How to best estimate the global burden of pertussis? Lancet Infectious Disease 3:413-418, 2003.
23. Luz P, Codeco C, Werneck G. The reseurgence of pertussis in developed countries : a problem for Brazil as well? Cad Saude Publica, Rio de Janeiro 19:1209-1213, 2003.
24. Posse R, Miceli I. Pertussis: its evolution in Argentina at the end of the twentieth century. Medicina (Bs Aires) 65:7-16, 2005.
25. Moraga F, Roca J, Méndez C. Epidemiology and surveillance of pertussis among infants in Catalonia, Spain during 1997-2001. Pediatr Infect Dis J 24:510-3, 2005.
26. Van Buynder P, Owen D, Vurdien J. Bordetella pertussis surveillance in England and Wales, 1995-1997. Epidemiol Infect 123:403-411, 1999.
27. Rendi-Wagner P, Kundi M, Mikolasek A et al. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: Estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine 24:5960-5965, 2006.
28. Wedelboe A, Van Rie A, Salmaso S et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatc Infect Dis J 24:S58-61, 2005.
29. Forsyth K, Tan T, Wirsing Von Kirsig C et al. Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J 24:S69-74, 2005.
30. Nelson JD. The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection. Am J Diseases Child 132:371-3, 1978.
31. Baptista P, Maqhalaes V, Rodrigues L et al. Sources of infection in household transmission of culture-confirmed pertussis in Brazil. Pediatr Infect Dis J 24:1027-1028, 2005.
32. Ward A, Caro J, Bassinet L. Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France. Infect Control Hosp Epidemiol 26:288-292, 2005.
33. Pascual F, McCall C, McMurtray A et al. Outbreak of pertussis among healthcare workers in a hospital surgical unit. Infect Control Hosp Epidemiol 27:546-552, 2006.
34. Van Rie A, Wendelboe A, Englund J. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis 24:S62-65, 2005.
35. Gonik B, Puder K, Gonik B et al. Seroprevalence of Bordetella pertussis antibdoes in mothers and their newborn infants. Infectious Diseases in Obstetrics and Gynaecology 13:59-61, 2005.
36. Healy C, Munoz F, Rench M et al. Prevalence of pertussis antibodies in maternal delivery, cord and infant serum. J Infect Dis 190:335-340, 2004.
37. Godfroid F, Denoel P, Poolman J. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence. Expert Rev Vaccines 4:757-778, 2005.
38. Weber C, Boursaux-Eude C, Coralie g et al. Polymorphism of Bordetella pertussis isolates ciculating the last ten years in France, where a single effective whole cell vaccine has been used for more than thirty years. J Clin Microbiol 39:4396-4403, 2001.
39. Forsyth K, Campins-Marti M, Caro J et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 39:1802-1809, 2004.
40. McIntyre P. Vaccination strategies for the prevention of neonatal pertussis. Expert Rev Vaccines 34:375-378, 2004.
41. Roduit C, Bozzotti P, Mielcarek N, Lambert PH, Del Giudice G, Locht C, Siegrist CA. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis. Infection and Immunity 70:3521-3528, 2002.
42. Taranger J, Trollfors B, Lagergard T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 181:1010-1013, 2000.
43. Plotkin SA, Cadoz M. The acellular pertussis vaccine trials: an interpretation. Pediatr Infect Dis 16:508-17, 1997.
44. Ward J, Cherry J, Chang S et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. New Engl J Med 353:1555-1563, 2005.
45. World Health Organization Immunization policy: Global Programme for Vaccines and Immunization - Expanded Programme on Immunization. WHOGPV/GEN/95.03 Rev.1. Geneva: World Health Organization; 1996.
46. Hull B, Lawrence G, Macintyre CR, McIntyre PB. Immunisation coverage: Australia 2001. Canberra: Commonwealth Department of Health and Ageing; 2001.
47. Taranger J, Trollfors B, Berfors E et al. Mass vaccination of children with pertussis toxoid - decreased incidence in both vaccinated and non vaccinated persons. Clin Infect Dis 33:1004-1010, 2001.
48. Van Rie A, Hethcote H. Adolescent and adult pertussis vaccination: compute simulations of five new strategies. Vaccine 22:3154-3165, 2004.
49. Siegrist C-A. Neonatal and early life vaccinology. Vaccine 19:3331-46, 2001.
50. Provenzano RW, et al Immunization and antibody response in the newborn infant. I. Pertussis inoculation within twenty-four hours of birth. New Engl J Med 273:959-961, 1965.
51. Halsey N, Galazka A. The efficacy of DPT and oral poliomyelitis immunization schedules inititated from birth to 12 weeks of age. Bull WHO 63:1151-69, 1985.
52. Booy R, Aitken SJ, Taylor S, et al. Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet 339:507-10, 1992.
53. Belloni C, De Silvestri A, Tinelli C, Avanzini MA, Marconi M et al. Immunogenecity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 111:1042-5, 2003.
54. Halasa N, O'Shea A, Lafleur B. Safety and Immunogenicity of an additional dose of DTPa given at birth. Abstract: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA, 2005.
55. Juretzko P, Fabian-Marx T, Haastert S, Giani G, Von Kries R, Wirsing von Konig CH. Pertussis in Germany: regional differences in management and vaccination status of hospitalized cases. Epidemiology and Infection 127:63-71, 2001.
56. Olin P, Gustafsson L, Barreto L et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 21:2015-2021, 2003.
57. Miller E, Ashworth LA, Redhead K, Thornton C, Waight PA, Coleman T. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine 15:51-60, 1997.
58. Edwards K. Pertussis: an important target for maternal immunization. Vaccine 21:3483-3486, 2003.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618